Omaha, NENCT04757116Now EnrollingIRB Ready

Benign Prostatic Hyperplasia (BPH) Clinical Trial in Omaha, NE

Access cutting-edge benign prostatic hyperplasia (bph) treatment through this clinical trial at a research site in Omaha. Study-provided care at no cost to qualified participants.

Sponsored by Olympus Corporation of the Americas

Quick Self-Assessment

See if you qualify for this Omaha location

Preparing your pre-screening questions…

Expert Care in Omaha

Access benign prostatic hyperplasia (bph) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related benign prostatic hyperplasia (bph) treatment provided free

Apply for This Omaha Location

Check if you qualify for this benign prostatic hyperplasia (bph) clinical trial in Omaha, NE

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Omaha

    Convenient for NE residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Omaha site if eligible
  4. 4Begin participation

About This Benign Prostatic Hyperplasia (BPH) Study in Omaha

The study objective is to evaluate the safety of the iTind device comparied to UroLift.

Sponsor: Olympus Corporation of the Americas

Who Can Participate

Inclusion Criteria

Diagnosis of lower urinary tract symptoms presumed to be secondary to benign prostatic enlargement causing bladder outlet obstruction for which treatment is recommended
Willing and able to provide informed consent
Males ≥ 50 years of age or older
PSA \< 4 ng/dl, ng/ml or if the PSA is 4 - 10 ng/dl, ng/ml, prostate cancer must be ruled out to the satisfaction of the Principal Investigator (PI) by local standard of care methods within prior 6 months
Prostate volume up to 75 cc (inclusive) documented by cross-sectional imaging (TRUS, MRI, etc.). Results from standard of care imaging may be accepted up to 6 months prior to Screening if the subject was not on 5-alpha reductase inhibitors (5ARIs) at that time
International Prostate Symptom Score (IPSS) ≥ 13
Maximum urinary flow rate (Qmax) of ≤ 15 mL/sec and ≥ 5 mL/sec (voided volume must be ≥ 125 mL)
Willing and able to complete all study visits including questionnaires at baseline and at follow-up visits

Exclusion Criteria

History of prostate cancer or suspected, should be ruled out to the satisfaction of the PI by local standard of care methods within prior 6 months
Confirmed or suspected bladder cancer within the last 2 years
History of acute bacterial prostatitis within the last 2 years
Median lobe obstruction of the prostate as confirmed by cross-sectional imaging
PSA value \> 10 ng/dl, ng/ml
Contraindicated for iTind or UroLift as determined by the PI
Neurogenic bladder and/or sphincter abnormalities due to Parkinson's disease, multiple sclerosis, cerebral vascular accident, diabetes or other neurological disorders that affect bladder function
Clinically significant bladder diverticulum
Diagnosed with urethral stricture, meatal stenosis, bladder neck contracture, rectal disease, artificial urinary sphincter, incompetent sphincter, urinary incontinence due to incompetent sphincter
Prior rectal surgery (other than hemorrhoidectomy) or history of rectal disease if the therapy may potentially cause injury to sites or previous rectal surgery (e.g., if a transrectal probe is used), pelvic radiotherapy or radical pelvic surgery, urinary diversion surgery, prostate surgery, balloon dilation, urethral stent implantation, laser prostatectomy, or any other invasive treatment to the prostate, or penile prosthesis that may prevent insertion of the iTind or UroLift device
An active urinary tract infection
Hematuria or cystolithiasis within the last 3 months
Prostate volume \> 75 cc
Post-void residual volume (PVR) \> 250 mL
Actively using catheterization or unable to void naturally
Unable to complete the required washout period for alpha blockers
Taking anti-platelet or anticoagulants (except low dose aspirin - 81 mg - 100 mg) within the last 7 days prior to randomization
Known or suspected allergy to nickel, titanium or polyester/polypropylene

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Omaha?

Yes, this clinical trial (NCT04757116) has an active research site in Omaha, NE that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Benign Prostatic Hyperplasia (BPH) Treatment Options in Omaha, NE

If you're searching for benign prostatic hyperplasia (bph) treatment options in Omaha, NE, this clinical trial (NCT04757116) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Omaha research site is actively enrolling participants for this clinical trial. You'll receive care from experienced benign prostatic hyperplasia (bph) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all benign prostatic hyperplasia (bph) clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in Omaha, NE

See all pulmonary embolism clinical trials recruiting in Omaha — not just this study.

Browse Pulmonary Embolism Trials in Omaha →

Browse More Trials by Condition

Pulmonary Embolism TrialsAnkylosing Spondylitis TrialsPulmonary Hypertension TrialsBenign Prostatic Hyperplasia TrialsInterstitial Cystitis TrialsRetinitis Pigmentosa TrialsRecurrent Pregnancy Loss TrialsAll Conditions →

Ready to Join in Omaha?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Omaha, NE